<?xml version="1.0" ?>
<document id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f">
  <chunk id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c0" text="Enhancement of anti-murine colon cancer immunity by fusion of a SARS fragment to a low-immunogenic carcinoembryonic antigen">
    <entity charOffset="27-39" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c0.e0" ontology_id="HP_0003003" text="colon cancer" type="phenotype"/>
    <entity charOffset="33-39" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c0.e1" ontology_id="HP_0002664" text="cancer" type="phenotype"/>
  </chunk>
  <chunk id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1" text="Background: It is widely understood that tumor cells express tumor-associated antigens (TAAs), of which many are usually in low immunogenicity; for example, carcinoembryonic antigen (CEA) is specifically expressed on human colon cancer cells and is viewed as a low-immunogenic TAA. How to activate host immunity against specific TAAs and to suppress tumor growth therefore becomes important in cancer therapy development. Results: To enhance the immune efficiency of CEA in mice that received, we fused a partial CEA gene with exogenous SARS-CoV fragments. Oral vaccination of an attenuated Salmonella typhimurium strain transformed with plasmids encoding CEA-SARS-CoV fusion gene into BALB/c mice elicited significant increases in TNF-Î± and IL-10 in the serum. In addition, a smaller tumor volume was observed in CT26/CEA-bearing mice who received CEA-SARS-CoV gene therapy in comparison with those administered CEA alone.">
    <entity charOffset="41-46" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e0" ontology_id="HP_0002664" text="tumor" type="phenotype"/>
    <entity charOffset="223-235" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e1" ontology_id="HP_0003003" text="colon cancer" type="phenotype"/>
    <entity charOffset="229-235" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e2" ontology_id="HP_0002664" text="cancer" type="phenotype"/>
    <entity charOffset="350-355" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e3" ontology_id="HP_0002664" text="tumor" type="phenotype"/>
    <entity charOffset="356-362" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e4" ontology_id="GO_0040007" text="growth" type="gene_function"/>
    <entity charOffset="394-400" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e5" ontology_id="HP_0002664" text="cancer" type="phenotype"/>
    <entity charOffset="785-790" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e6" ontology_id="HP_0002664" text="tumor" type="phenotype"/>
    <pair e1="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e0" e2="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e4" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.p0" relation="true"/>
    <pair e1="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e1" e2="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e4" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.p1" relation="true"/>
    <pair e1="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e2" e2="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e4" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.p2" relation="true"/>
    <pair e1="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e3" e2="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e4" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.p3" relation="true"/>
    <pair e1="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e4" e2="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e5" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.p4" relation="true"/>
    <pair e1="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e4" e2="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.e6" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c1.p5" relation="true"/>
  </chunk>
  <chunk id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c2" text="The administration of fusing CEA-SARS-CoV fragments may provide a promising strategy for strengthening the anti-tumor efficacy against low-immunogenic endogenous tumor antigens.">
    <entity charOffset="162-167" id="6b749617eb4a9f2760720a1b2a061cd0d45f9e3f.c2.e0" ontology_id="HP_0002664" text="tumor" type="phenotype"/>
  </chunk>
</document>
